Clinical trials: Autoimmune / Connective Tissue Diseases
Systemic-Onset Juvenile Idiopathic Arthritis
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
1. Main objective: To test the efficacy of anakinra treatment in children or young adults with corticosteroid-resistant or -dependent Systemic-Onset Juvenile Idiopathic Arthritis (SO-JIA) 2.
- Trial name
- NCT00339157
- Testing
- Anakinra, Pneumo23
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Juvenile Idiopathic Arthritis, Diabetes type1
Host-microbiota-environment Interactions
Two types of inflammatory and autoimmune diseases (excluding monogenic diseases) can be distinguished in children: those similar to adult diseases but with an early onset (type 1 diabetes, inflammatory diseases of the…
- Conditions
- Juvenile Idiopathic Arthritis, Diabetes type1, Inflammatory Bowel Diseases
- Trial name
- MIP-1 (NCT05176795)
- Testing
- Stool sample
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Polyendocrinopathies, Autoimmune
Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an autosomal recessive disease caused by mutations in the autoimmune regulator (AIRE) gene, characterized by the clinical triad of chronic mucocutaneous…
- Trial name
- APECED2 (NCT03800056)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Lille
Rheumatoid Arthritis
Early Migration in a High Congruent Rotating Platform Total Knee Prosthesis Design
The aim of this study is to accurately assess the relationship between knee joint kinematics and migration of the tibial component of a high congruent, rotating platform total knee prosthesis by using fluoroscopy synchronised in…
- Trial name
- ROCC (NCT01102829)
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Leiden University Medical Center
Primary Sjögren's Syndrome
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method…
- Trial name
- NCT02495129
- Testing
- VAY736 lower dose, VAY736 higher dose
- Sponsor
- Novartis Pharmaceuticals
Immune Deficiency, Immune Dysregulation Disorder
Allergy and Immunology Natural History Study
This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation.
- Conditions
- Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
- Trial name
- NCT05584488
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Systemic Lupus Erythematosus
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study
In patients with systemic lupus erythematosus, immunosuppressive therapy to the point of complete immune ablation and hematopoietic stem cell recovery.
- Trial name
- NCT00271934
- Testing
- Immune ablation and hematopoietic stem cell support.
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Northwestern University
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Trial name
- NCT07089121
- Testing
- Descartes-08
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cartesian Therapeutics
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Rheumatoid Arthritis, Muscle Atrophy
Muscle Wasting and Rheumatoid Arthritis Flares
People living with Rheumatoid Arthritis (RA) often present with low muscle mass compared to their healthy counterparts. This affects their mobility, overall health and quality of life.
- Trial name
- NCT06400316
- Testing
- Amino Acid Supplement
- Volunteers
- 40 people
- Sponsor
- Leeds Beckett University
Juvenile Idiopathic Arthritis
Cost of Care for Juvenile Idiopathic Arthritis
This project seeks to collect data on healthcare utilization and expenditure rates in Juvenile Idiopathic Arthritis (JIA) patients from across the US, correlate these costs with disease activity and outcome measures and determine…
- Trial name
- NCT01469897
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- The Cleveland Clinic
Lupus Erythematosus, Systemic
Validation of Patient E-tool to Measure Systemic Lupus Activity
Validation of a self-questionnaire (SLEDAI-P/LUPIN) completed by the patient to measure the activity of the systemic lupus, in order to improve the patient's empowerment.
- Trial name
- OPTIMISE (NCT05763225)
- Where
- 31 sites in France, Guadeloupe and 1 more
- Volunteers
- 450 people
- Sponsor
- Association Francaise du Lupus et Autres Maladies Auto-immunes (AFL+)
Autoinflammatory Disease, Juvenile Dermatomyositis
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
Purpose: The purpose of this protocol is 1. To comprehensively evaluate patients with autoinflammatory diseases clinically, genetically and immunologically at the autoinflammatory disease clinic at the NIH. 2.
- Trial name
- NCT00059748
- Where
- United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Juvenile Idiopathic Arthritis
Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA. 1.
- Trial name
- Enbrel-JIA (NCT01145352)
- Testing
- Etanercept (genetical recombination)
- Where
- Japan
- Volunteers
- 113 people
- Sponsor
- Pfizer
Systemic Lupus Erythematosus
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
The purpose of this study is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while…
- Trial name
- NCT07630714
- Testing
- Anifrolumab + APFS
- Where
- 39 sites in Australia, Belgium and 8 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Lupus Nephritis
Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Prospective, multi-center, randomized, controlled, trial to compare tacrolimus with mycophenolate mofetil (MMF) for induces complete remission in lupus nephritis patients. The study duration is one year.
- Trial name
- NCT01580865
- Testing
- Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Ramathibodi Hospital
Juvenile Idiopathic Arthritis (JIA)
HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis
Methodology: Randomized, double-blind, AB/BA cross-over study with a washout period of 12 weeks. Treatment Duration: 8 weeks per group General Objectives: To assess the efficacy and safety of multiple intravenous infusions of…
- Trial name
- NCT06623240
- Testing
- allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Lupus Erythematosus, Scleroderma
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be…
- Conditions
- Lupus Erythematosus, Scleroderma, Myositis, Vasculitis
- Trial name
- ESSAi (NCT05251415)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- University Hospital, Toulouse
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals